Trial · NCT01922011
Safety and Efficacy Study of Daptomycin Compared to Active Comparator in Pediatric Participants With Acute Hematogenous Osteomyelitis (AHO) (MK-3009-006)
NCT01922011, Phase 3, Completed, Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); results first posted 2017-06-23
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. Safety and Efficacy Study of Daptomycin Compared to Active Comparator in Pediatric Participants With Acute Hematogenous Osteomyelitis (AHO) (MK-3009-006). Trials, record NCT01922011. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01922011
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Safety and Efficacy Study of Daptomycin Compared to Active Comparator in Pediatric Participants With Acute Hematogenous Osteomyelitis (AHO) (MK-3009-006)
- NCT number
- NCT01922011
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 149 participants, actual
- Lead sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Conditions
- Acute Hematogenous Osteomyelitis
- Interventions
- Daptomycin, Vancomycin (or equivalent), Nafcillin (or equivalent)
- First posted
- 2013-08-14
- Last updated
- 2018-08-28
- Other registries' IDs
- eudract:2013-000864-28
- Results first posted
- 2017-06-23
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of Participants With Clinical Improvement in the 3 General Categories of Pain, Inflammation, and Limb Function Based on the Investigator's Overall Assessment of Severity of Each of the Symptom Categories. | Up to study Day 5 | Clinical improvement was based on the Investigator's overall assessment of severity of each of the 3 general symptom categories of Pain, Inflammation, and Limb Function. Based on this evaluation, a participant was considered to have met criteria for clinical improvement according to the following definition: If 3 general categories are present at baseline: at least a 1-point improvement (i.e. severe to moderate, moderate to mild, mild to absent) in at least 2 of the general categories and no worsening in the other. If 2 general categories are present at baseline: at least a 2-point improvement (i.e. severe to mild, moderate to absent) in at least 1 of the general categories and no worsening or new findings in the others OR at least a 1-point improvement in both and no new findings in the other. If 1 general category is present at baseline: at least a 2-point improvement (i.e., severe to mild, moderate to absent) in that category and no new findings in the others. |
| Secondary | Percentage of Participants With Clinical Improvement Measured as a Composite End Point of Pain, Inflammation, Limb Function, Body Temperature, and C-reactive Protein at End-of IV (EOIV) Therapy Visit. | Up to study Day 5 | A participant had a favorable outcome in this composite endpoint if all 3 of the following criteria were met: Clinical improvement in the general symptom categories of Pain, Inflammation, and Limb Function on or before Study Day 5; Body temperature ≤ 38°C (100.4°F) over the preceding 24 hours; and C-reactive Protein (CRP) decreased from baseline for participants who had a baseline CRP \>ULN (upper limit of normal)) or remain \<=ULN for participants who had a baseline \<=ULN on or before Study Day 5. The EOIV visit is within 24 hours after the last dose of IV study drug and before switch to optional open label (PO) therapy, if applicable. |
| Secondary | Percentage of Participants With a Favorable Clinical Outcome | Baseline (within 48 hours prior to first dose of IV study drug) - and up to Test of Cure (21-35 days after last dose of IV study drug) (up to Day 77) | Favorable clinical outcomes are clinical recovery and clinical cure. Clinical cure is defined as resolution of all acute symptoms of AHO or improvement to such an extent that no further intravenous antibacterial therapy is required. Clinical recovery is defined as clinical improvement in the composite end point three general categories of Pain, Inflammation, and Limb Function on or before Study Day 5, and no development of new symptoms of AHO; body temperature ≤ 38°C (100.4°F) for 24 hours; no new or additional bone or joint infection (e.g., abscess, spreading to other osseous or articular locations) such that no further antibacterial therapy or surgery are required; no hematogenous metastatic infection (e.g., abscess in liver, spleen, lung; other bones) or bacteremia.. The End of Therapy (EOT) visit is within 48 hours of last dose of PO therapy. |
| Secondary | Percentage of Participants With a Clinical Cure Categorized by Baseline Pathogen at Test of Cure | Baseline (within 48 hours prior to first dose of IV study drug) - and Test of Cure (21-35 days after last dose of IV study drug) (up to Day 77) | At Test Of Cure (TOC) clinical cure is defined as resolution of all acute symptoms of AHO or improvement to such an extent that no further antibacterial therapy is required. Favorable microbiological outcomes are either eradication where the source specimen demonstrated absence of the original baseline pathogen; or presumed eradication where the source specimen was not available to culture, and the subject was assessed as a clinical cure. To have a favorable microbiological response, the outcome for each participant's baseline pathogen must be favorable (eradicated or presumed eradicated). Other pathogens include Arcanobacterium haemolyticum, Gram positive cocci, Staphylococcus epidermidis, Streptococcus dysgalactiae, Streptococcus mitis group and Streptococcus pyogenes. |
| Secondary | Percentage of Participants With Sustained Clinical Improvement | Baseline (within 48 hours prior to first dose of IV study drug) - up to Test of Cure (21-35 days after last dose of IV study drug) (up to Day 77) | Sustained clinical improvement was defined as participants with clinical improvement who further met the definition of clinical cure. Clinical improvement was in the three general categories of Pain, Inflammation, and Limb Function on or before Study Day 5. Clinical cure is defined as resolution of all acute symptoms of AHO or improvement to such an extent that no further intravenous antibacterial therapy is required. The EOT visit is within 48 hours of last dose of PO therapy. |
| Secondary | Percentage of Participants With a Favorable Microbiological Response Categorized by Baseline Pathogen at Test of Cure | Baseline (within 48 hours prior to first dose of IV study drug) - and Test of Cure (21-35 days after last dose of IV study drug) (up to Day 77) | Favorable microbiological outcomes are either eradication where the source specimen demonstrated absence of the original baseline pathogen; or presumed eradication where the source specimen was not available to culture, and the subject was assessed as a clinical cure. For a favorable microbiological response, the outcome for each baseline pathogen must be eradicated or presumed eradicated. Other pathogens include Arcanobacterium haemolyticum, Gram positive cocci, Staphylococcus epidermidis, Streptococcus dysgalactiae, Streptococcus mitis group and Streptococcus pyogenes. |
| Other | Number of Participants With 1 or More Adverse Events (AEs) | Administration of first dose up to approximately six and a half months after last dose of study drug | An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, clinically significant laboratory finding, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product |
| Other | Number of Participants With 1 or More Serious Adverse Events (SAEs) | Administration of first dose through the last follow-up visit; an expected time of up to 6.5 months | An SAE is any untoward medical occurrence that at any dose results in death; is life threatening; requires in-patient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; or is a congenital anomaly/birth defect. |
| Other | Concentration of Serum Creatine Kinase (CK) | Baseline and End of Therapy IV (up to Day 42) | Serum was collected at Baseline and at End of Therapy IV, from which the concentration of CK was determined. |
| Other | Change From Baseline in Number of Participants With Abnormal Focused (Peripheral) Neurological Assessments | Baseline and up to Test of Cure (21-35 days after last dose of IV study drug) (up to Day 77) | Focused neurological examinations include assessments of alertness, sensation, pupillary reflex and tracking, peripheral reflexes (biceps, patellar tendon, ankle jerk, and plantar response), muscle tone and strength (upper and lower limbs), coordination (finger to nose), and tremor of the hands/fingers. |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes14
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percentage of Participants With Clinical Improvement in the 3 General Categories of Pain, Inflammation, and Limb Function Based on the Investigator's Overall Assessment of Severity of Each of the Symptom Categories. | Up to study Day 5 | All randomized participants who received any amount of IV study drug and who had a confirmed or suspected diagnosis of AHO, excluding those with confirmed culture of a gram-negative organism from any baseline specimen. | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Clinical Improvement Measured as a Composite End Point of Pain, Inflammation, Limb Function, Body Temperature, and C-reactive Protein at End-of IV (EOIV) Therapy Visit. | Up to study Day 5 | All randomized participants who received any amount of IV study drug and who had a confirmed diagnosis of AHO (Categories I, II and III), excluding participants with confirmed culture of a gram-negative organism from any baseline specimen and who did not have all clinical assessments performed at the time point. | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With a Favorable Clinical Outcome | Baseline (within 48 hours prior to first dose of IV study drug) - and up to Test of Cure (21-35 days after last dose of IV study drug) (up to Day 77) | All randomized participants who received any amount of IV study drug and who had a confirmed diagnosis of AHO (Categories I, II and III), excluding participants with confirmed culture of a gram-negative organism from any baseline specimen | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With a Clinical Cure Categorized by Baseline Pathogen at Test of Cure | Baseline (within 48 hours prior to first dose of IV study drug) - and Test of Cure (21-35 days after last dose of IV study drug) (up to Day 77) | All randomized participants who received IV study drug and had a confirmed diagnosis of AHO, excluding participants with confirmed culture of a gram-negative organism; but including those where at least one bacterial pathogen was isolated from an appropriate microbiological specimen at baseline. | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Sustained Clinical Improvement | Baseline (within 48 hours prior to first dose of IV study drug) - up to Test of Cure (21-35 days after last dose of IV study drug) (up to Day 77) | All randomized participants who received any amount of IV study drug and who had a confirmed or suspected diagnosis of AHO, excluding those with confirmed culture of a gram-negative organism from any baseline specimen; and had non-missing clinical outcome. | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With a Favorable Microbiological Response Categorized by Baseline Pathogen at Test of Cure | Baseline (within 48 hours prior to first dose of IV study drug) - and Test of Cure (21-35 days after last dose of IV study drug) (up to Day 77) | All randomized participants who received IV study drug and had a confirmed diagnosis of AHO, excluding participants with confirmed culture of a gram-negative organism; but including those where at least one bacterial pathogen was isolated from an appropriate microbiological specimen at baseline. | Percentage of participants | NUMBER |
| OTHER_PRE_SPECIFIED | Number of Participants With 1 or More Adverse Events (AEs) | Administration of first dose up to approximately six and a half months after last dose of study drug | Treated participants based on the treatment received | Participants | NUMBER |
| OTHER_PRE_SPECIFIED | Number of Participants With 1 or More Serious Adverse Events (SAEs) | Administration of first dose through the last follow-up visit; an expected time of up to 6.5 months | Treated participants based on the treatment received | Participants | NUMBER |
| OTHER_PRE_SPECIFIED | Concentration of Serum Creatine Kinase (CK) | Baseline and End of Therapy IV (up to Day 42) | Treated participants based on the treatment received | U/L | MEAN |
| OTHER_PRE_SPECIFIED | Change From Baseline in Number of Participants With Abnormal Focused (Peripheral) Neurological Assessments | Baseline and up to Test of Cure (21-35 days after last dose of IV study drug) (up to Day 77) | Data were only summarized for each visit; but not analyzed. |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 outcomesResults by group57
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
Percentage of Participants With Clinical Improvement in the 3 General Categories of Pain, Inflammation, and Limb Function Based on the Investigator's Overall Assessment of Severity of Each of the Symptom Categories. | Daptomycin | 77.5 | 95% Confidence Interval 67.7 to 87.2 | Percentage of participants | |
Percentage of Participants With Clinical Improvement in the 3 General Categories of Pain, Inflammation, and Limb Function Based on the Investigator's Overall Assessment of Severity of Each of the Symptom Categories. | Vancomycin or Nafcillin | 82.9 | 95% Confidence Interval 74.0 to 91.7 | Percentage of participants | |
| Percentage of Participants With Clinical Improvement Measured as a Composite End Point of Pain, Inflammation, Limb Function, Body Temperature, and C-reactive Protein at End-of IV (EOIV) Therapy Visit. | Daptomycin | 71.0 | 95% Confidence Interval 60.3 to 81.7 | Percentage of participants | |
| Percentage of Participants With Clinical Improvement Measured as a Composite End Point of Pain, Inflammation, Limb Function, Body Temperature, and C-reactive Protein at End-of IV (EOIV) Therapy Visit. | Vancomycin or Nafcillin | 76.5 | 95% Confidence Interval 66.4 to 86.6 | Percentage of participants | |
| Percentage of Participants With a Favorable Clinical Outcome | Daptomycin | At End of IV (EOIV) Therapy (n= 71,69) | 85.9 | 95% Confidence Interval 77.8 to 94.0 | Percentage of participants |
| Percentage of Participants With a Favorable Clinical Outcome | Vancomycin or Nafcillin | At End of IV (EOIV) Therapy (n= 71,69) | 91.3 | 95% Confidence Interval 84.7 to 98.0 | Percentage of participants |
| Percentage of Participants With a Favorable Clinical Outcome | Daptomycin | At End of Therapy (EOT) (n= 71,69) | 83.1 | 95% Confidence Interval 74.4 to 91.8 | Percentage of participants |
| Percentage of Participants With a Favorable Clinical Outcome | Vancomycin or Nafcillin | At End of Therapy (EOT) (n= 71,69) | 89.9 | 95% Confidence Interval 82.7 to 97.0 | Percentage of participants |
| Percentage of Participants With a Favorable Clinical Outcome | Daptomycin | At Test Of Cure (TOC) (n= 71,70) | 81.7 | 95% Confidence Interval 72.7 to 90.7 | Percentage of participants |
| Percentage of Participants With a Favorable Clinical Outcome | Vancomycin or Nafcillin | At Test Of Cure (TOC) (n= 71,70) | 87.1 | 95% Confidence Interval 79.3 to 95.0 | Percentage of participants |
1 to 10 of 57Source ClinicalTrials.gov
See all 57 results by groupParticipant flow10
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Daptomycin | 75 | |
| Overall Study | STARTED | Vancomycin or Nafcillin | 74 | |
| Overall Study | Treated | Daptomycin | 73 | |
| Overall Study | Treated | Vancomycin or Nafcillin | 73 | |
| Overall Study | Treatment Actually Received | Daptomycin | 74 | |
| Overall Study | Treatment Actually Received | Vancomycin or Nafcillin | 72 | |
| Overall Study | COMPLETED | Daptomycin | 69 | |
| Overall Study | COMPLETED | Vancomycin or Nafcillin | 69 | |
| Overall Study | NOT COMPLETED | Daptomycin | 6 | |
| Overall Study | NOT COMPLETED | Vancomycin or Nafcillin | 5 |
Source ClinicalTrials.gov
Adverse events38
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Constipation | Gastrointestinal disorders | Daptomycin | 1 | 74 | 1 |
| other | Constipation | Gastrointestinal disorders | Vancomycin or Nafcillin | 6 | 72 | 6 |
| other | Diarrhoea | Gastrointestinal disorders | Daptomycin | 1 | 74 | 1 |
| other | Diarrhoea | Gastrointestinal disorders | Vancomycin or Nafcillin | 4 | 72 | 4 |
| other | Vomiting | Gastrointestinal disorders | Daptomycin | 3 | 74 | 3 |
| other | Vomiting | Gastrointestinal disorders | Vancomycin or Nafcillin | 6 | 72 | 6 |
| other | Pyrexia | General disorders | Daptomycin | 2 | 74 | 2 |
| other | Pyrexia | General disorders | Vancomycin or Nafcillin | 5 | 72 | 6 |
| other | Nasopharyngitis | Infections and infestations | Daptomycin | 0 | 74 | 0 |
| other | Nasopharyngitis | Infections and infestations | Vancomycin or Nafcillin | 4 | 72 | 5 |
1 to 10 of 38Source ClinicalTrials.gov
See all 38 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Daptomycin | ||
| Total, all-cause mortality | Vancomycin or Nafcillin | ||
| Total, other adverse events | Daptomycin | 6 | 74 |
| Total, other adverse events | Vancomycin or Nafcillin | 24 | 72 |
| Total, serious adverse events | Daptomycin | 5 | 74 |
| Total, serious adverse events | Vancomycin or Nafcillin | 4 | 72 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 32639465 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons3
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Daptomycin vs Vancomycin or Nafcillin: Number of Participants With 1 or More Adverse Events (AEs) | Trial comparisons |
| Daptomycin vs Vancomycin or Nafcillin: Number of Participants With 1 or More Serious Adverse Events (SAEs) | Trial comparisons |
| Daptomycin vs Vancomycin or Nafcillin: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01922011
GET https://conductscience.org/api/trials/v1/NCT01922011/results?page=2